Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Urinary Bladder Neoplasms 1Surgical Wound Infection 1Skin Neoplasms 1Neoplasms 1Leukemia, Myeloid, Acute 1Inflammation 1Infections 1Genetic Predisposition to Disease 1Breast Neoplasms 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Cephalexin × Clear all
NCT05020574 2026-03-18

Microbiome and Association With Implant Infections

University of California, San Francisco

Phase 2 Recruiting
200 enrolled
Breast

Breast Neoplasms, Genetic Predisposition to Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡